EGUALEN

Possibly Marketed Outside US

Details

Stereochemistry	ACHIRAL
Molecular Formula	C15H18O3S
Molecular Weight	278.367
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

CCC1=C2C=CC=C(C=C2C(=C1)S(O)(=O)=O)C(C)C

InChI

InChIKey=NARQSHREEUXZBT-UHFFFAOYSA-N

InChI=1S/C15H18O3S/c1-4-11-9-15(19(16,17)18)14-8-12(10(2)3)6-5-7-13(11)14/h5-10H,4H2,1-3H3,(H,16,17,18)

HIDE SMILES / InChI

Description

Egualen is an azulene derivative developed for the treatment of peptic ulcer and marketed in Japan under the tradename Azuloxa. The drug exerts its antiulcer activity by antagonizing TXA2 production.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
thromboxane A2 signaling pathway 5	Antagonist 2,849
gastric mucosal blood circulation 6	Activator 1,447
mucus secretion 8	Activator 1,447

Conditions

Condition	Modality	Targets	Highest Phase	Product
Gastric ulcer 74	Primary		Approved 8,583	AZULOXA

C_max

Value	Dose	Analyte	Population
1272 ng/mL	15 mg single, oral	EGUALEN plasma	Homo sapiens
1417.7 ng/mL	15 mg single, oral	EGUALEN plasma	Homo sapiens
0.6 μg/mL	10 mg single, oral	EGUALEN plasma	Homo sapiens
0.58 μg/mL	15 mg single, oral	EGUALEN plasma	Homo sapiens
1.84 μg/mL	30 mg single, oral	EGUALEN plasma	Homo sapiens

AUC

Value	Dose	Analyte	Population
10744.1 ng × h/mL	15 mg single, oral	EGUALEN plasma	Homo sapiens
11710.9 ng × h/mL	15 mg single, oral	EGUALEN plasma	Homo sapiens
6 μg × h/mL	10 mg single, oral	EGUALEN plasma	Homo sapiens
7.2 μg × h/mL	15 mg single, oral	EGUALEN plasma	Homo sapiens
18.2 μg × h/mL	30 mg single, oral	EGUALEN plasma	Homo sapiens

T_1/2

Value	Dose	Analyte	Population
7.8 h	15 mg single, oral	EGUALEN plasma	Homo sapiens
7.9 h	15 mg single, oral	EGUALEN plasma	Homo sapiens
4.6 h	10 mg single, oral	EGUALEN plasma	Homo sapiens
5.9 h	15 mg single, oral	EGUALEN plasma	Homo sapiens
4.4 h	30 mg single, oral	EGUALEN plasma	Homo sapiens

F_unbound

Value	Dose	Co-administered	Analyte	Population
1.7%			EGUALEN plasma	Homo sapiens
0.2%	15 mg single, oral		EGUALEN plasma	Homo sapiens

Doses

Doses

Show entries

Dose	Population	Adverse events
1.2 g 1 times / day multiple, oral Highest studied dose	healthy, ADULT

Showing 1 to 1 of 1 entries

Previous1Next

PubMed

PubMed

Show entries

Title	Date	PubMed
Inhibitory effect of egualen sodium: a new stable derivative of azulene on histamine release from mast cell-like cells in the stomach.	2001	11729358

Showing 1 to 1 of 1 entries

Previous1Next

Sample Use Guides

In Vivo Use Guide

1 tablet (15 mg) or 0.6 g of 2.5% granules twice a day.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Show entries

Name

Type

Language

EGUALEN

Official Name

English

Egualen [WHO-DD]

Preferred Name

English

egualen [INN]

Common Name

English

3-ETHYL-7-ISOPROPYL-1-AZULENESULFONIC ACID

Systematic Name

English

Showing 1 to 4 of 4 entries

Previous1Next

Show entries

Classification Tree

Code System

Code

Agent Affecting Nervous System

NCI_THESAURUS

C29698

Showing 1 to 1 of 1 entries

Previous1Next

Show entries

Code System

Code

Type

Description

DRUG CENTRAL

993

PRIMARY

EPA CompTox

DTXSID2052861

PRIMARY

FDA UNII

17VM9WN49U

PRIMARY

CAS

99287-30-6

PRIMARY

CHEBI

85542

PRIMARY

Showing 1 to 5 of 11 entries

Previous1 2 3Next

ACTIVE MOIETY


					17VM9WN49U

EGUALEN

SALT/SOLVATE (PARENT)


					3368L0W034

EGUALEN SODIUM

SALT/SOLVATE (PARENT)

249501B040

EGUALEN SODIUM HYDRATE

SMILES

InChI

Description<div class="info-popup-container"><div><span class="pop-sub-key ">Sources:&nbsp;</span><span class="pop-sub-val"><span class="ext-link"><a target="_self" href="http://www.ncbi.nlm.nih.gov/pubmed/23568973">http://www.ncbi.nlm.nih.gov/pubmed/23568973</a></span></span></div></div>

Originator

Approval Year

Targets

Conditions

Cmax

AUC

T1/2

Funbound

Doses

PubMed

Sample Use Guides

Description

C_max

T_1/2

F_unbound